HLA-DP-mismatching has a large effect on the risks of GVHD-related outcomes. HRs (diamonds) and 95% CIs (lines) show GVHD-related outcomes for (A) HLA 16/16–matched unrelated recipients and (B) HLA-DP GVH-mismatched unrelated recipients as compared with sibling recipients. HRs for GVHD-related endpoints were adjusted for the risk factors listed in Table 1, and the HRs for recurrent or progressive malignancy were adjusted for low-risk disease (chronic myeloid leukemia in chronic phase and refractory anemia), high-risk disease (malignancy not in remission), and intermediate-risk disease (all others).